14
Dec
By Ernst & Young
The UK is expected to exit the European Union from 29 March 2019. This has consequences for UK life sciences operations. Have you planned your response?
Life sciences companies trading in both the European Union and the UK will face changes post-Brexit:
A UK-held medicinal product Marketing Authorization may not be mutually recognized in other EU countries
A hard border between the UK and EU will present cross-border trade challenges
Quality Release requirements may change
Navigating the changes...